• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharm (NQ: SUPN )

    31.54 -0.28 (-0.88%)
    Streaming Delayed Price Updated: 9:53 AM EDT, Sep 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,373
    Open 31.73
    Bid (Size) 31.56 (2)
    Ask (Size) 31.64 (4)
    Prev. Close 31.82
    Today's Range 31.54 - 31.73
    52wk Range 21.99 - 35.44
    Shares Outstanding 53,145,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
    Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million. 
    Via Benzinga

    Performance

    YTD
    +13.74%
    +13.74%
    1 Month
    -9.81%
    -9.81%
    3 Month
    +17.21%
    +17.21%
    6 Month
    -3.69%
    -3.69%
    1 Year
    +10.43%
    +10.43%

    More News

    Read More
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Announces Second Quarter 2024 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
    Via Chartmill
    Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
    Via InvestorPlace
    NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    Trading SMID Biotech Stocks In A Volatile Market
    Via Talk Markets
    Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
    Via Chartmill
    Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
    Via InvestorPlace
    Supernus Announces First Quarter 2024 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.